Table 2. Overview on patent activities in the AC field with emphasis on mAC inhibitors.
Indication | Patent Titles | Key Patents and Applications | Proposed Use of AC-Inhibitors | AC inhibitors/compounds (name listed as written in patent) |
---|---|---|---|---|
Senescence | Signals and molecular species involved in senescence | WO2009139511 US7482134 |
|
|
| ||||
Heart Disease | Treatment of cardiac disease including heart attack, myocardial apoptosis, and heart failure, comprises administering type 5 adenylyl cyclase inhibiting compound | WO2009099676 |
|
|
New 9-substituted adenine derivatives are adenylyl cyclase inhibitors used to treat cardiac function and performance and as cytostatics. | WO2002004475 US7045309 |
|||
| ||||
Intestinal fluid loss | Treatment of intestinal fluid loss e.g. diarrhea or condition associated with increased 3′-5′-adenosine monophosphate levels involves administering composition comprising e.g. cycloalkenone derivatives, and tricyclic and bicyclic derivatives | WO2001094369 US20020188016 US20020032228 EP1353664 |
|
|
| ||||
Fibropro-liferative vasculopathy | New adenine derivatives, used to treat e.g. chronic allograft rejection, vascular restenosis, congestive heart failure, psoriasis, tumor growth, diabetic retinopathy and arteriosclerosis, are adenyl cyclase inhibitors | WO2002040481 US6887880 |
|
|
| ||||
Circadian Rhythm | Use of composition comprising inhibitor of adenylyl cyclase (e.g. purine site inhibitor) for elongation of circadian rhythm and for treating e.g. jet lag, familial advanced sleep phase syndrome and shift lag | WO2007135387 |
|
|
| ||||
Wound healing | Pharmaceutical composition useful for promoting wound healing in mammals, preferably humans, comprises adenylyl cyclase inhibitor and lysophosphatidic acid inhibitor | WO2010126260 |
|
|
We performed a keyword search in the Thompson Innovation patent literature databases including the Derwent World Patents Index (http://www.thomsoninnovation.com/ti/contentsets/patents/). The search term was: CTB=((adenylyl or adenylate) cyclase inhibitor*) OR CTB=(ADCY* inhibitor *) and the date of search was June 5th, 2011. The initial 247 hits were individually reviewed, the patents dealing with mAC inhibitors were identified, and the information contained therein was condensed and compared according to the criteria of the Table. The usefulness of the patents will be critically determined by the selectivity of the compounds for mACs or specific mAC isoforms relative to other targets. As is outlined in the text and Table 1, specificity of nucleoside-based inhibitors among AC isoforms and off-target effects are a great concern. One prominent example in this regard is SQ 22,536 (also referred to as 9-(tetrahydro-2-furanyl)-9H-purin-6-amine (THFA or 9-THF-Ade)), mentioned in several patents. The different nomenclature of this compound in various publications [13-16,65] may have caused some confusion in the literature regarding compound identity.